Table 3 Patient characteristics and univariate analysis of second-line overall survival after second-line chemotherapy
Characteristic | Patients (n = 26) | Median 2nd-line OS (95% CI), months | HR (95% CI) | p-value | |
|---|---|---|---|---|---|
Median age, years (range) | 63 (43–82) | 9.92 (4.76–NA) | – | – | |
Age categorisation | < 63 | 13 | 7.33 (7.23–NA) | 1.34 (0.50–3.65) | 0.56 |
≥ 63 | 13 | 10.22 (1.91–NA) | – | – | |
Sex | Male | 20 | 9.92 (4.76–NA) | 0.93 (0.30–2.89) | 0.9 |
Female | 6 | 7.23 (3.22–NA) | – | – | |
Asbestos exposure | Yes | 8 | 7.34 (2.30–NA) | 2.00 (0.68–5.87) | 0.2 |
No or unknown | 18 | 10.22 (3.22–NA) | – | – | |
Histology | Epithelioid | 14 | 12.55 (4.76–NA) | 1.11 (0.41–3.04) | 0.83 |
Others | 12 | 8.62 (1.91–NA) | – | – | |
ECOG PS | 0–1 | 25 | 9.92 (3.22–NA) | NA | 0.56 |
2 | 1 | NA (NA–NA) | – | – | |
Distant metastasis | Yes | 14 | 10.22 (2.30–NA) | 1.00 (0.37–2.70) | 1.0 |
No | 12 | 7.33 (4.76–NA) | – | – | |
Cycles of platinum doublet | < 6 | 9 | 1.79 (0.66–NA) | 0.23 (0.07–0.80) | 0.013 |
≥ 6 | 17 | 10.22 (7.23–NA) | – | – |